SCHEMBL2839844

SCHEMBL2839844

CNC(=O)[C@]1(CO[Si](C)(C)C(C)(C)C)CC[C@H](c2ccc(OCc3ccccc3F)cc2)N1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 6/20 0.47
SCN3A Q9NY46 7/20 0.42
SCN1A P35498 1/20 0.41
SCN4A P35499 1/20 0.41
SCN7A Q01118 1/20 0.41
SCN5A Q14524 1/20 0.41
SCN9A Q15858 1/20 0.41
SCN2A Q99250 1/20 0.41
SCN8A Q9UQD0 1/20 0.41
SCN10A Q9Y5Y9 1/20 0.41
MAOB P27338 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2B6 P20813 1/20 0.40
CYP2C19 P33261 1/20 0.40
LPAR1 Q92633 3/20 0.38
LPAR5 Q9H1C0 3/20 0.38
MMP1 P03956 3/20 0.37
MMP13 P45452 1/20 0.37
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2830547 0.91 KCNH2 (0.50) KCNH2SCN3ASCN1ASCN4ASCN7A
SCHEMBL2835535 0.91 KCNH2 (0.52) KCNH2SCN3ASCN1ASCN4ASCN7A
SCHEMBL2833974 0.89 KCNH2 (0.52) KCNH2SCN3ASCN1ASCN4ASCN7A
SCHEMBL2835319 0.89 KCNH2 (0.49) KCNH2SCN3ASCN1ASCN4ASCN7A
SCHEMBL1104544 0.84 KCNH2 (0.45) KCNH2SCN3ASCN1ASCN4ASCN7A
SCHEMBL483491 0.84 KCNH2 (0.46) KCNH2SCN3ASCN1ASCN4ASCN7A
SCHEMBL483598 0.82 KCNH2 (0.49) KCNH2SCN3ASCN1ASCN4ASCN7A
SCHEMBL2834682 0.82 KCNH2 (0.56) KCNH2SCN3ASCN1ASCN4ASCN7A
SCHEMBL13320320 0.81 KCNH2 (0.48) KCNH2SCN3ASCN1ASCN4ASCN7A
SCHEMBL2836380 0.81 KCNH2 (0.55) KCNH2SCN3ASCN1ASCN4ASCN7A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130583-A1 PROLINAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS GLAXO GROUP LIMITED (GB) 2010-05-27 US disclosed
EP-2129655-A1 PROLINAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS Glaxo Group Limited (GB) 2009-12-09 EP disclosed
WO-2008122546-A1 PROLINAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS GLAXO GROUP LIMITED (GB) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130583-A1 PROLINAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS SCN1A, SCN3A, SCN2A KCNH2 22/4885SCN3A 2/4885SCN1A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.